{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Neogen Corp. Hits Day Low of $9.63 Amid Price Pressure
Neogen Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has faced significant stock volatility, with notable declines over various timeframes. Despite these challenges, the company maintains a low debt-to-equity ratio and demonstrates healthy long-term growth in net sales, supported by strong institutional holdings.
Neogen Corp. Hits New 52-Week High of $11.43, Signaling Recovery
Neogen Corp. has achieved a new 52-week high of USD 11.43, rebounding from a low of USD 3.87. Despite a challenging year with a 30.03% decline, the company maintains a market capitalization of USD 2,465 million and exhibits stable financial metrics within the pharmaceuticals and biotechnology sector.
Neogen Corp. Stock Hits Day Low of $5.57 Amid Price Pressure
Neogen Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has faced significant challenges, with a notable decline in stock price and returns over the past year. Key financial indicators reveal low return on capital employed and a high debt-equity ratio, highlighting ongoing struggles in the market.
Is Neogen Corp. technically bullish or bearish?
As of August 12, 2025, Neogen Corp. shows a mildly bearish technical trend with mixed signals from various indicators, significantly underperforming the S&P 500 year-to-date and over the past year.
Is Neogen Corp. overvalued or undervalued?
As of July 30, 2024, Neogen Corp. is considered overvalued and risky, with a high P/E ratio of 281, a low Price to Book Value of 0.42, and poor performance reflected in a YTD return of -53.29% and a 10Y return of -84.97%, significantly underperforming compared to its peers and the S&P 500.
Is Neogen Corp. technically bullish or bearish?
As of June 18, 2025, Neogen Corp. is in a bearish trend with moderate strength, supported by bearish monthly indicators and daily moving averages, despite some mixed signals from the KST and MACD.
Is Neogen Corp. overvalued or undervalued?
As of July 30, 2024, Neogen Corp. is considered overvalued with a risky valuation grade, highlighted by a P/E ratio of 281, poor financial performance with a ROCE of 1.61% and ROE of 0.15%, and a significant year-to-date stock decline of 60.71% compared to a 2.44% gain for the S&P 500.
Who are in the management team of Neogen Corp.?
As of March 2022, Neogen Corp.'s management team includes CEO John Adent and Lead Independent Chairman James Borel, along with several independent directors: Dr. William Boehm, Dr. Ronald Green, Mr. G. Bruce Papesh, Mr. James Tobin, and Ms. Darci Vetter.
What does Neogen Corp. do?
Neogen Corp. develops and markets products for food and animal safety within the Pharmaceuticals & Biotechnology industry. As of February 2025, it has net sales of $221 million, a net profit of -$11 million, and a market cap of approximately $1.15 billion.
How big is Neogen Corp.?
As of Jun 18, Neogen Corp. has a market capitalization of 1,145.96 million, classifying it as a Small Cap company, with net sales of 905.99 million and a net profit of -485.27 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
